$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
What are the 8 early signs of lung cancer? How effective is alectinib treatment?
2025-10-19 11:44:20
Check Details
Who can compete with him? AMG510 is launched to combat KRAS gene mutation lung cancer
2025-10-19 11:44:20
Check Details
Does anyone sell ramucirumab in Sichuan? What is the price
2025-10-19 11:44:20
Check Details
How effective is Rybrevant, the blockbuster new drug for lung cancer? Where can I buy it in Chongqing?
2025-10-19 11:44:20
Check Details
How to use EGFRex20ins+ non-small cell lung cancer targeting drug Rybrevant? Are there any side effects?
2025-10-19 11:44:20
Check Details
What should I do if resistance to ramucirumab develops? What to pay attention to
2025-10-19 11:44:20
Check Details
Just now! Lung cancer targeted drug Mobotinib is on the market! How much do you know about it?
2025-10-19 11:44:20
Check Details
How much does it cost to buy EGFR-MET bispecific antibody Rybrevant in Hubei? How to use?
2025-10-19 11:44:20
Check Details
How effective is the blockbuster new drug Rybrevant? Are there any serious side effects of Rybrevant?
2025-10-19 11:44:20
Check Details
The response rate of mobotinib, a drug targeting EGFR gene mutation in non-small cell lung cancer, reaches 43%_ Kanghule
2025-10-19 11:44:20
Check Details
Is Mobotinib on the market? Is there a place to sell it in Wuhan?
2025-10-19 11:44:20
Check Details
The anti-tumor drug Pozitinib has a lung cancer disease response rate of up to 90%
2025-10-19 11:44:20
Check Details
1
2
...
3960
3961
3962
3963
3964
3965
3966
...
4155
4156
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
2
Vemurafenib (Zelboraf) Complete Medication Guide
3
Durvalumab Safety Profile: Managing Immune-Related Adverse Events (irAEs) in Clinical Practice
4
Zolbetuximab Combination Therapy: Global Efficacy and Safety Profile in CLDN18.2-Positive Advanced Gastric Cancer
5
Managing Mitotane Resistance in Adrenocortical Carcinoma: Strategies and Global Options
6
Trametinib & Dabrafenib in 2026: A Global Guide to Treating BRAF-Mutant Cancers
7
A Guide to Safely Stopping Mitotane: Why Tapering is Essential and How to Manage
8
Pemigatinib Efficacy: Significantly Improving Survival in FGFR2-Fusion Cholangiocarcinoma
9
Erlotinib: Targeting EGFR Mutations to Precisely Inhibit Non-Small Cell Lung Cancer Growth
10
Tofacitinib: The Role and Considerations of an Oral JAK Inhibitor in Autoimmune Disease Treatment
11
Tucatinib: Redefining the Treatment Landscape for HER2-Positive Cancers with High Selectivity
12
Complete Guide to Garsorasib Resistance Mechanisms and Follow-Up Treatments